Life-Saving Cancer Drug Sees 1400% Price Hike
CAPITALISM, 1 Jan 2018
teleSUR – TRANSCEND Media Service
The potentially life-saving medicine is used to treat patients suffering from brain tumors and Hodgkin’s lymphoma.
27 Dec 2017 – The price of the cancer drug lomustine has soared to nearly 1400 percent since 2013, after it was bought by a startup in Miami, U.S.
While originally sold by Bristol-Myers Squib for decades under the brand name CeeNU for about US$50 a capsule, it now goes for US$768 per pill, thanks to startup NextSource’s price hikes.
According to Henry S. Friedman, a professor of neurosurgery at Duke University School of Medicine, NextSource has engaged in “price-gouging”, telling the Wall Street Journal, “People are not going to be able to afford it, or they’re going to pay a lot of money and have financial liability.”
The medicine is used to treat patients suffering from brain tumors and Hodgkin’s lymphoma, and can be potentially life-saving.
NextSource CEO Robert DiCrisci has justified the gargantuan price hikes by saying it sets the price based on the costs it incurs in developing the medication.
DISCLAIMER: In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Join the discussion!
We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.